Physician

Jeffrey W. Langford, M.D.

According to 2025 Medicare claims, Jeffrey Langford, M.D. (NPI: 1346360690) practices internal medicine in the Warner Robins, GA market, with the plurality of this provider's patient population coming from Houston, GA. This provider's primary affiliated billing organization is LANGFORD ALLERGY LLC (NPI: 1215351291; TIN: 46-4393166) and primary practice location at 31061-0850. Langford is affiliated with the TC2, LLC (ACO ID: A3365), participating under the MSSP model.

Langford's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 208 traditional Medicare patients, billed 68,838 HCPCS/CPT codes, and received $1,315,371 in Medicare payments. The top billing code was 99457 (Management using the results of remote vital sign monitoring per calendar month, first 20 minutes). Part D data shows 2,662 prescription claims across 491 beneficiaries totaling $1,100,917 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 555 claims. Open Payments data shows 22 records totaling $2,622. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $44,387 to $1,315,371. Similarly, Part D prescription costs have moved sharply higher in recent years, from $64,935 to $1,100,917. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $364 to $23,855.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	84	4,767	$44,387
2016	126	7,356	$67,460
2017	210	13,036	$126,021
2018	299	16,155	$149,776
2019	324	19,375	$291,819
2020	265	17,327	$372,263
2021	294	25,562	$695,363
2022	364	34,897	$837,099
2023	300	54,981	$1,079,230
2024	208	68,838	$1,315,371

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	89	453	$64,935
2016	137	803	$143,458
2017	204	1,224	$278,881
2018	246	1,553	$378,026
2019	291	1,729	$360,133
2020	329	2,087	$469,760
2021	405	2,356	$886,169
2022	411	2,452	$1,076,265
2023	417	2,396	$1,325,553
2024	491	2,662	$1,100,917

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	15	$147
2016	N/R	24	$58,679
2017	N/R	N/R	N/R
2018	N/R	23	$70,841
2019	N/R	97	$143,664
2020	N/R	280	$505,534
2021	N/R	368	$900,900
2022	N/R	451	$1,045,989
2023	N/R	544	$1,346,448
2024	35	555	$1,397,862

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99457	Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	22	215	$32
99458	Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes	22	511	$26
J1306	Injection, inclisiran, 1 mg	61	33,512	$10
95165	Professional service for preparation and provision of 1 or more antigens	90	5,390	$9
96372	Injection of drug or substance under skin or into muscle	93	471	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	248	13,500	$286,775
Hizentra	Immun Glob G(Igg)/Pro/Iga 0-50	26	728	$205,774
Xolair	Omalizumab	24	672	$83,073
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	12	336	$77,410
Dupixent Pen	Dupilumab	13	364	$48,646

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1551	Injection, immune globulin (cutaquig), 100 mg	N	11	92	$545,111
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	92	$438,368
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	66	$390,837
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	11	103	$18,393
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	44	$3,115

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	22	$2,622	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey W. Langford, M.D.?

Tedicare shows public-source Medicare data for Jeffrey W. Langford, M.D. (NPI 1346360690), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey W. Langford, M.D. have ACO affiliation data?

Jeffrey W. Langford, M.D. is shown with ACO affiliation data for TC2, LLC (MSSP, ACO ID A3365).

What billing organization is linked to Jeffrey W. Langford, M.D.?

Jeffrey W. Langford, M.D. is linked to LANGFORD ALLERGY LLC (billing NPI 1215351291) in the available physician profile data.

Does Jeffrey W. Langford, M.D. have Open Payments data?

Jeffrey W. Langford, M.D. has 22 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.